GMAB vs MGTX: fair value comparison
Genmab A/S and MeiraGTx Holdings plc · Updated 2026-10-19
MGTX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, MGTX currently ranks higher by quality score.
| GMAB | MGTX | |
|---|---|---|
| Verdict | Overvalued | No estimate yet |
| Last price | $37.00 | $9.28 |
| 12-month range | $23.85–$38.48 | $6.99–$14.97 |
| Rank by discount to fair value | #76 of 108 Healthcare | — |
| Rank by quality score | #91 of 301 Healthcare | #90 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Contracting |
| Revenue growth | Declining | — |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: GMAB fair value analysis · MGTX fair value analysis